Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-center, Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Tazarotene 0.045% Lotion (Arazlo) for Treating Postinflammatory Erythema and Postinflammatory Hyperpigmentation in Subjects With Acne

NCT05704114 is registered in ClinicalTrials.gov with Dr. Emmy Graber as lead sponsor.

NCT NCT05704114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05704114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-center, Pilot Study to Evaluate the Efficacy, Safety, and Tolerability of Tazarotene 0.045% Lotion (Arazlo) for Treating Postinflammatory Erythema and Postinflammatory Hyperpigmentation in Subjects With Acne
Lead sponsor
Dr. Emmy Graber
Phase
Phase 4
Overall status
Completed
Start date
February 1, 2021
Completion date
May 1, 2022
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acne vulgaris, erythema, post inflammatory hyperpigmentation, post inflammatory pigmentation change, skin scarring